Use of isavuconazole in a patient with voriconazole-induced QTc prolongation

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12712. Epub 2017 Jun 20.

Abstract

A 22-year-old woman with cystic fibrosis developed QTc interval prolongation following lung transplantation in the setting of voriconazole therapy. After the discontinuation of voriconazole and initiation of isavuconazole, her QTc interval normalized. This case highlights the unique property of QTc interval shortening by isavuconazole among the triazole antifungals.

Keywords: Aspergillus; QTc; isavuconazole; torsades; voriconazole.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / adverse effects
  • Antifungal Agents / therapeutic use*
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / surgery
  • Female
  • Humans
  • Long QT Syndrome / chemically induced*
  • Long QT Syndrome / etiology
  • Lung Transplantation / adverse effects*
  • Nitriles / therapeutic use*
  • Pyridines / therapeutic use*
  • Triazoles / therapeutic use*
  • Voriconazole / adverse effects*
  • Young Adult

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
  • Voriconazole